Clinical trials: Pneumococcal Vaccine
Pneumococcal Infections
A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
This is a Phase 1 first-in-human, randomized, controlled, observer-blinded study with a 2-arm parallel design. Healthy adults aged 18 to 49 years of age with no history of pneumococcal vaccination will be randomized equally to…
- Trial name
- NCT02955160
- Testing
- Multivalent, Tdap
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Pneumococcal
Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants
This study will examine the consistency of 3 batches of the Pneumosil vaccine by looking at the immune response in infants. In addition, the study will compare the immunogenicity of the Pneumosil vaccine to another…
- Trial name
- NCT03197376
- Testing
- Pneumosil, Synflorix
- Where
- The Gambia
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- PATH
HIV, Pneumonia
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus.
- Conditions
- HIV, Pneumonia, Infections, Pneumococcal
- Trial name
- NCT05794191
- Testing
- Vaccine Administration
- Where
- United States
- Volunteers
- 350,399 people
- Sponsor
- Pfizer
Pneumococcal Disease, Pneumococcal Carriage
Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes just under four million serious infections every year. It is normal for pneumococcus bacteria to live in the noses of healthy adults and children as part of the…
- Trial name
- RATIONALE-15 (NCT06731374)
- Testing
- PCV15, Streptococcus pneumoniae serotype 3
- Where
- 2 sites in United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Hepatitis B, Acellular Pertussis
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal…
- Conditions
- Hepatitis B, Acellular Pertussis, Tetanus, Poliomyelitis
- Trial name
- NCT00463437
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Infanrix hexa
- Where
- 63 sites in Germany, Poland and 1 more
- Volunteers
- 1,437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Pneumococcal Infections
A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)
The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.
- Trial name
- NCT00127153
- Testing
- V110, pneumococcal vaccine polyvalent
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Autoimmune Rheumatic Diseases
Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs
This clinical trial aims to evaluate the effect of temporary methotrexate (MTX) discontinuation on the humoral immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adult patients with autoimmune rheumatic…
- Trial name
- MTX-PCV20-ARD (NCT07242092)
- Testing
- Pneumococcal Vaccine
- Where
- Brazil
- Volunteers
- 192 people
- Sponsor
- University of Sao Paulo General Hospital
Otitis Media, Pneumococcal Infections
Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes
This was a randomized, double-blinded multicenter cohort study of Finnish children aged 2 to 24 months. The study was designed to evaluate the efficacy of two 7-valent pneumococcal conjugate vaccines (PncCRM and PncOMPC)…
- Trial name
- NCT00378417
- Testing
- 7-valent pneumococcal-CRM197 conjugate vaccine, 7-valent pneumococcal-OMPC conjugate vaccine
- Where
- 5 sites in Finland
- Volunteers
- 3,075 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving…
- Trial name
- NCT06720038
- Testing
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumococcal Pneumonia, Pneumonia, Bacterial
Phase I to Test a New Pneumococcal Vaccine
To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers.
- Trial name
- NCT03303976
- Testing
- Bioconjugate pneumococcal vaccine, Multivalent plain polysaccharide vaccine
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Pneumococcal Infection
Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)
The purpose of this study is to determine that revaccination of Pneumococcal Vaccine is well tolerated and produces an immune response in older adults.
- Trial name
- NCT00560950
- Testing
- pneumococcal 23v polysaccharide vaccine
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule
The purpose of this study is to assess the safety and reactogenicity of 3 different dose levels of inactivated poliovirus vaccine based on Sabin strains (sIPV) in healthy participants, using conventional Salk IPV (cIPV) as an…
- Trial name
- NCT03566940
- Testing
- sIPV, cIPV
- Where
- 3 sites in Philippines
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Pneumococcal Disease
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
This is a Phase 3, randomized, double-blind study with a 4-arm parallel design. Adults 18 through 49 years of age with no history of pneumococcal vaccination will be randomized in a 2:2:2:1 ratio to receive a single dose of…
- Trial name
- NCT03828617
- Testing
- 20vPnC, 13vPnC
- Where
- 21 sites in United States
- Volunteers
- 1,710 people, healthy volunteers welcome
- Sponsor
- Pfizer
Immunisation Against Streptococcus Pneumoniae
Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka
This PMS study aims to collect safety and reactogenicity data of Synflorix™ in healthy infants and children of the local population as per the licensing requirement of the Sri Lankan regulatory authority.
- Trial name
- NCT01803425
- Testing
- Synflorix™ data collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections, HIV Infections
Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women
HIV-infected people and pregnant women are at risk of developing severe pneumococcal disease. The purpose of this study is to compare the safety and immune response to two pneumococcal vaccines in HIV-infected pregnant women.
- Trial name
- NCT01443117
- Testing
- PPV-23 Vaccine, PCV-13 Vaccine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumococcal Immunization, Healthy Volunteers
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called…
- Trial name
- NCT06975878
- Testing
- PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine
- Where
- 49 sites in Belgium, Czechia and 6 more
- Volunteers
- 1,092 people, healthy volunteers welcome
- Sponsor
- Sanofi
Haemophilus Influenzae, Streptococcus Pneumoniae
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease.
- Trial name
- NCT00849069
- Testing
- GSK2231395A, TwinrixTM
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
- Trial name
- NCT05297578
- Testing
- 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine
- Where
- 20 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumococcal Infections
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)
This study will evaluate whether the aluminum-adjuvanted or the non-adjuvanted formulation of the candidate pneumococcal vaccine (V114) is non-inferior to Prevnar 13® based on immune responses to the 13 serotypes in common…
- Trial name
- NCT01215188
- Testing
- V114 Aluminum-adjuvanted, V114 Non-adjuvanted, Prevnar 13®
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
The 13-valent pneumococcal conjugate vaccine (13vPnC) is being developed for adults to prevent pneumococcal diseases such as meningitis (inflammation of the brain lining), septicemia (blood poisoning), and pneumonia (inflammation…
- Trial name
- NCT00492557
- Testing
- 13-valent pneumococcal conjugate vaccine, 13vPnC + TIV
- Volunteers
- 1,185 people, healthy volunteers welcome
- Sponsor
- Pfizer